CompletedNCT00678418
Naltrexone or placebo for opioid dependence after inpatient care
About this title
Read the official source —Medication studyAges 18+RussiaAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- MoscowSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 250
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Russia
- Age range
- Over 18 Years
- Official registry ID
- NCT00678418
- Official title
Show the full official title
Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence
Get this study by email
Recruitment & locations
CompletedMoscow, Russia · Russia
Questions about this study
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including VIVITROL® 380 mg and Placebo.
Who was this study for?
Listed age limits: from 18 years.
